SpyBiotech completes subject enrolment in Phase I HCMV vaccine trial
The trial enrolled 120 healthy adults aged 18-50 years over a six-month dosing schedule in the UK.
The trial enrolled 120 healthy adults aged 18-50 years over a six-month dosing schedule in the UK.
